Market Cap 3.61B
Revenue (ttm) 1.53B
Net Income (ttm) 312.44M
EPS (ttm) N/A
PE Ratio 10.78
Forward PE 11.38
Profit Margin 20.37%
Debt to Equity Ratio 0.51
Volume 877,969
Avg Vol 1,455,488
Day's Range N/A - N/A
Shares Out 66.31M
Stochastic %K 25%
Beta 0.04
Analysts Strong Sell
Price Target $81.58

Company Profile

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area wi...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 978 671 8001
Fax: 978 671 8860
Address:
201 Burlington Road, South Building, Bedford, United States
Keywest20
Keywest20 Nov. 14 at 3:07 PM
$CATX $LNTH $PSTV $RADX you forgot Merc they’re buying out to citel for over $9 billion 
1 · Reply
RadioIsotope25
RadioIsotope25 Nov. 14 at 2:39 PM
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 4:58 AM
$LNTH is currently trading at $53.12, below the 30-day moving average (MA30) of $55.09 and the 50-day moving average (MA50) of $53.94, indicating bearish sentiment. The RSI of 42.96 suggests the stock is approaching oversold territory, providing potential for a rebound. The recent 60-day high of $62.00 and low of $49.67 establishes a trading range that can guide our strategy. Directional bias leans bearish due to the price being below key moving averages, but the RSI indicates a potential reversal could occur soon. Suggested entry point is $52.50, slightly below the current price to capture a bounce. Set a stop-loss at $49.50 to mitigate risk. Target 1 is $55.00, aligning with the MA30, and Target 2 is $58.00, near the midpoint of the recent high-low range. Monitor the stock closely for any changes in momentum. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 3:04 AM
$LNTH: The last close at $53.37 indicates the stock is currently below its 30-day moving average (MA30) of $54.98 and its 50-day moving average (MA50) of $53.96, suggesting a bearish trend. The RSI at 40.33 indicates that the stock is approaching oversold territory but is not yet there, implying potential for a reversal if buying pressure increases. The 60-day high of $62.00 and low of $49.67 provide a range that can be utilized for setting targets. Suggested trade plan: Enter at $53.50 to capture a potential reversal. Set a stop loss at $52.50 to limit risk. Target 1 at $55.00, aligning with the MA30, and Target 2 at $56.00, just below the 60-day high. This plan allows for a calculated approach while respecting current market indicators. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 2:40 AM
$LNTH: The last close at $53.37 indicates the stock is currently below its 30-day moving average (MA30) of $54.98 and its 50-day moving average (MA50) of $53.96, suggesting a bearish trend. The RSI at 40.33 indicates that the stock is approaching oversold territory but is not yet there, implying potential for a reversal if buying pressure increases. The 60-day high of $62.00 and low of $49.67 provide a range that can be utilized for setting targets. Suggested trade plan: Enter at $53.50 to capture a potential reversal. Set a stop loss at $52.50 to limit risk. Target 1 at $55.00, aligning with the MA30, and Target 2 at $56.00, just below the 60-day high. This plan allows for a calculated approach while respecting current market indicators. https://privateprofiteers.com
0 · Reply
morty104
morty104 Nov. 11 at 8:50 PM
$ASPI $BMY $CATX $LNTH $PFE hahaha! I freakin toldja so…
1 · Reply
NoRiskNoFun
NoRiskNoFun Nov. 11 at 8:36 PM
$CATX $ASPI $LNTH $PFE $BMY buy out imminent!
0 · Reply
RadioIsotope25
RadioIsotope25 Nov. 11 at 7:59 PM
Lantheus bought more a few days back at $6.00 building its ownership up to 14.5% $RADX $LNTH
1 · Reply
Live2ride
Live2ride Nov. 10 at 7:19 PM
$LNTH Still got 300 million to repurchase. ............. On July 31, 2025, the Lantheus Holdings, Inc. board of directors approved a stock buyback initiative of up to $400 million. This program replaced a previous buyback plan from November 2024. In the third quarter of 2025, Lantheus repurchased $100 million of its common stock under this plan.
0 · Reply
JarvisFlow
JarvisFlow Nov. 10 at 4:52 PM
Truist Securities has updated their rating for Lantheus Holdings ( $LNTH ) to Hold with a price target of 61.
0 · Reply
Latest News on LNTH
Lantheus Holdings, Inc. (LNTH) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 9:09 PM EDT - 3 months ago

Lantheus Holdings, Inc. (LNTH) Q2 2025 Earnings Call Transcript


Lantheus Holdings: Reassessing The Buy Thesis

Aug 6, 2025, 10:09 AM EDT - 3 months ago

Lantheus Holdings: Reassessing The Buy Thesis


Keywest20
Keywest20 Nov. 14 at 3:07 PM
$CATX $LNTH $PSTV $RADX you forgot Merc they’re buying out to citel for over $9 billion 
1 · Reply
RadioIsotope25
RadioIsotope25 Nov. 14 at 2:39 PM
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 4:58 AM
$LNTH is currently trading at $53.12, below the 30-day moving average (MA30) of $55.09 and the 50-day moving average (MA50) of $53.94, indicating bearish sentiment. The RSI of 42.96 suggests the stock is approaching oversold territory, providing potential for a rebound. The recent 60-day high of $62.00 and low of $49.67 establishes a trading range that can guide our strategy. Directional bias leans bearish due to the price being below key moving averages, but the RSI indicates a potential reversal could occur soon. Suggested entry point is $52.50, slightly below the current price to capture a bounce. Set a stop-loss at $49.50 to mitigate risk. Target 1 is $55.00, aligning with the MA30, and Target 2 is $58.00, near the midpoint of the recent high-low range. Monitor the stock closely for any changes in momentum. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 3:04 AM
$LNTH: The last close at $53.37 indicates the stock is currently below its 30-day moving average (MA30) of $54.98 and its 50-day moving average (MA50) of $53.96, suggesting a bearish trend. The RSI at 40.33 indicates that the stock is approaching oversold territory but is not yet there, implying potential for a reversal if buying pressure increases. The 60-day high of $62.00 and low of $49.67 provide a range that can be utilized for setting targets. Suggested trade plan: Enter at $53.50 to capture a potential reversal. Set a stop loss at $52.50 to limit risk. Target 1 at $55.00, aligning with the MA30, and Target 2 at $56.00, just below the 60-day high. This plan allows for a calculated approach while respecting current market indicators. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 2:40 AM
$LNTH: The last close at $53.37 indicates the stock is currently below its 30-day moving average (MA30) of $54.98 and its 50-day moving average (MA50) of $53.96, suggesting a bearish trend. The RSI at 40.33 indicates that the stock is approaching oversold territory but is not yet there, implying potential for a reversal if buying pressure increases. The 60-day high of $62.00 and low of $49.67 provide a range that can be utilized for setting targets. Suggested trade plan: Enter at $53.50 to capture a potential reversal. Set a stop loss at $52.50 to limit risk. Target 1 at $55.00, aligning with the MA30, and Target 2 at $56.00, just below the 60-day high. This plan allows for a calculated approach while respecting current market indicators. https://privateprofiteers.com
0 · Reply
morty104
morty104 Nov. 11 at 8:50 PM
$ASPI $BMY $CATX $LNTH $PFE hahaha! I freakin toldja so…
1 · Reply
NoRiskNoFun
NoRiskNoFun Nov. 11 at 8:36 PM
$CATX $ASPI $LNTH $PFE $BMY buy out imminent!
0 · Reply
RadioIsotope25
RadioIsotope25 Nov. 11 at 7:59 PM
Lantheus bought more a few days back at $6.00 building its ownership up to 14.5% $RADX $LNTH
1 · Reply
Live2ride
Live2ride Nov. 10 at 7:19 PM
$LNTH Still got 300 million to repurchase. ............. On July 31, 2025, the Lantheus Holdings, Inc. board of directors approved a stock buyback initiative of up to $400 million. This program replaced a previous buyback plan from November 2024. In the third quarter of 2025, Lantheus repurchased $100 million of its common stock under this plan.
0 · Reply
JarvisFlow
JarvisFlow Nov. 10 at 4:52 PM
Truist Securities has updated their rating for Lantheus Holdings ( $LNTH ) to Hold with a price target of 61.
0 · Reply
Live2ride
Live2ride Nov. 10 at 3:54 PM
$LNTH Come on management, shorts are killing your stock. Step up and buy em back.
1 · Reply
ZacksSCR
ZacksSCR Nov. 10 at 3:09 PM
$LNTH: Can AD Franchise Offset Pylarify Drag? https://buff.ly/eztHqoZ
0 · Reply
TradingFUD
TradingFUD Nov. 9 at 6:06 PM
$LNTH 2025 July Rates Compared to Proposed 2026 Rates. Neuraceq (Florbetaben f18): July 2025 rate, $1,273.76 2026 new rate, $1,577.13 = 23.8% increase in reimbursement. $XBI $LLY
0 · Reply
Qaz94
Qaz94 Nov. 8 at 9:34 AM
$LNTH I know the issue with Pilarify being less competitive and needing to find other sources of income while it holds as long as possible, but haven’t been following the latest events and it seems that they managed to beat estimates. Could someone explain why the shares are back to 51? I’m considering jumping back in
1 · Reply
st6387
st6387 Nov. 8 at 2:11 AM
$LNTH The updated adjusted EPS guidance provided on 11-6 for 2025 is $5.50 - $5.65 per share v $5.50 - $5.70 per share provided on 8-6 in connection with Q2 earnings. However, during Q3, the company purchased $100 million of stock at $56 per share. This reduced the outstanding share count by 1.7 million shares, or about 2.5% of the outstanding shares (in fact, the weighted average shares outstanding during Q2 were 70.3 million v 67.7 million during Q3, a 3.7% decrease in shares outstanding). So, the guidance is flat but the share count is down meaningfully, meaning the actual earnings of the company are now being guided lower for the year. While this doesn’t matter for EPS purposes, it speaks to a continued degradation of the business. Said another way, the Q2 guidance of a $5.60 midpoint adjusted EPS implied adjusted fully diluted earnings of $394 million for 2025 whereas the Q3 guidance of midpoint $5.57 implies adjusted fully diluted earnings of $377 million for 2025.
0 · Reply
RadioIsotope25
RadioIsotope25 Nov. 8 at 12:24 AM
$LNTH https://youtu.be/d1lhPMFcrvY
0 · Reply
CH_Expat
CH_Expat Nov. 7 at 6:34 PM
$LNTH What the hell happened in this two years?
0 · Reply
Live2ride
Live2ride Nov. 7 at 6:13 PM
$LNTH Hey LNTH ... time to buy more shares back!
0 · Reply
RadioIsotope25
RadioIsotope25 Nov. 7 at 3:27 PM
Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies Companies with most LU-177 drugs in development $RADX 4 $LNTH 2 $MNPR 1 Point Bio acquired for theirs for $1.4 billion by $LLY https://www.prnewswire.com/news-releases/lilly-to-acquire-point-biopharma-to-expand-oncology-capabilities-into-next-generation-radioligand-therapies-301945243.html
0 · Reply
RadioIsotope25
RadioIsotope25 Nov. 7 at 2:22 PM
$RADX 4 LU-177 assets (Same active drug as blockbuster Pluvicto) https://radiopharmtheranostics.com/our-pipeline/ $LNTH
0 · Reply
Live2ride
Live2ride Nov. 6 at 8:35 PM
$LNTH Why didn't I buy puts at the open this morning?
1 · Reply
HappE
HappE Nov. 6 at 7:36 PM
$LNTH Paul on his exit: "As for me, my decision’s personal. I’ve got nine grandchildren, and actually, I think number nine was the tipping point for me. When I came into the role, it was not with any expectation that this would be a long-term assignment, and that I came in to rebuild a pipeline, rebuild an R&D organization, and position this company for sustained long-term growth. I feel really, really good about doing that."
0 · Reply